Scope
This NICE summary focuses on recognising menopause, selecting symptom treatment, assessing important comorbidities and reviewing therapy. Most routine symptom-management recommendations concern people aged 40 or over; premature ovarian insufficiency before 40 has a separate diagnostic and replacement pathway. Hormone replacement therapy (HRT) decisions require an individual discussion of benefits, risks, route, formulation and duration, with specialist input for complex medical or cancer histories.
Written by House with AI assistance · AI-assisted source check 29 October 2026.
This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.
Identify menopause without unnecessary testing
- In otherwise healthy people aged 45 or over with compatible symptoms, identify perimenopause clinically from newly started vasomotor symptoms plus menstrual change. Identify menopause after at least 12 months without a period when not using hormonal contraception; after hysterectomy use the symptom pattern. [1]
- Do not use FSH to identify menopause during combined oestrogen/progestogen contraception or high-dose progestogen. Consider FSH confirmation only at ages 40–45 with compatible symptoms including menstrual change, or under 40 when menopause is suspected. [1]
- Discuss symptom variability, contraception, bone health and physical activity to maintain muscle strength. Offer psychological support when early menopause at ages 40–44 causes distress, with psychology referral if needed. [1]
Treat vasomotor and related symptoms
- For menopause-associated vasomotor symptoms in people aged 40 or over, offer HRT after individual assessment. Consider menopause-specific CBT alongside HRT, when HRT is contraindicated, or when the person prefers not to take it. [1]
- When HRT is unsuitable, NICE identifies fezolinetant as an option for moderate-to-severe menopause-associated vasomotor symptoms, subject to its separate technology appraisal. Do not routinely use SSRIs, SNRIs or clonidine as first-line treatment for vasomotor symptoms alone. [1]
- Consider HRT for depressive symptoms that began around the same time as other menopause symptoms but do not meet depression diagnostic criteria. Suspected or diagnosed depression also needs the depression guideline pathway; it must not be reduced to a menopause symptom alone. [1]
- For sleep difficulties associated with vasomotor symptoms, consider menopause-specific CBT alongside other options, when those options are contraindicated, or when the person prefers not to try them. Consider testosterone for menopause-associated low sexual desire only when HRT alone has not worked. [1]
Manage genitourinary symptoms
- Without a personal history of breast cancer, offer vaginal oestrogen for menopause-associated genitourinary symptoms, including alongside systemic HRT. Review regularly, and explain that absorption into blood is minimal compared with systemic HRT and serious adverse effects are very rare. [1]
- For menopause-associated genitourinary symptoms in people without a personal history of breast cancer, vaginal oestrogen can be used alone or with non-hormonal moisturisers/lubricants. Consider those non-hormonal options if vaginal oestrogen is contraindicated or declined; consider vaginal prasterone after these approaches are ineffective or not tolerated, and oral ospemifene if local treatment is impractical. [1]
- With a personal history of breast cancer, offer non-hormonal moisturisers or lubricants first. Consider vaginal oestrogen for persistent symptoms despite non-hormonal treatment; when adjuvant aromatase inhibitors are being used, work with the breast cancer specialist to select treatment. [1]
- For vaginal oestrogen after breast cancer, assess the individual recurrence risk and explain that its effect on recurrence remains unknown despite low systemic absorption. Do not offer vaginal laser treatment for menopausal genitourinary symptoms outside a randomised controlled trial. [1]
Choose treatment with medical history in view
- Discuss combined versus oestrogen-only HRT, oral versus transdermal routes, hormone types, sequential versus continuous treatment, dose and duration. Use the full outcome tables and discussion aid to explain individual benefits and risks rather than presenting one risk estimate as universal. [1]
- For increased VTE risk, including BMI above 30 kg/m², consider transdermal rather than oral HRT. For high VTE risk such as strong family history or hereditary thrombophilia, consider haematology assessment before HRT. [1]
- With previous coronary heart disease or stroke, HRT should be discussed and, if appropriate, offered by a menopause expert. With a personal history or high risk of breast cancer, offer information on all management options and specialist menopause referral. [1]
- Do not prescribe combined or oestrogen-only HRT to prevent cardiovascular disease, whether primary or secondary prevention, or to prevent dementia. Treatment for menopausal symptoms is a separate decision. [1]
Start, monitor and stop HRT safely
- When HRT is chosen for menopause symptoms, offer combined HRT if a uterus is present and oestrogen-only HRT after total hysterectomy. Use the lowest effective dose and consider condition-specific expert advice when a comorbidity may be affected. [1]
- For people with a uterus, explain that bleeding can be common during the first 6 months of systemic HRT or within 3 months of a dose/preparation change. Ask about it at the 3-month review and advise prompt medical help for unscheduled bleeding beyond these windows; use the appropriate cancer/bleeding assessment pathway. [1]
- Review each menopause symptom treatment at 3 months for efficacy and tolerability, then annually or earlier for ineffectiveness, side effects or adverse events. Refer for menopause expertise if symptoms fail to improve or side effects continue. [1]
- When stopping HRT, offer gradual reduction or immediate cessation: tapering may reduce short-term symptom recurrence but does not change longer-term symptoms. Stop systemic HRT if breast cancer is diagnosed, following the breast cancer pathway. [1]
Use a separate pathway before40
- Before 40, diagnose premature ovarian insufficiency from compatible symptoms, including absent/infrequent periods, and elevated FSH on 2 samples 4–6 weeks apart. Account for hysterectomy and clinical/family history; do not diagnose from one blood test or routinely use anti-Müllerian hormone. [1]
- Offer HRT or combined hormonal contraception for premature ovarian insufficiency unless contraindicated, for example by hormone-sensitive cancer. Explain continuing hormonal treatment until at least the natural menopause age, unless contraindicated, and that HRT itself is not contraceptive. If hormonal treatment is contraindicated, give advice on bone and cardiovascular health and symptom management. [1]
Limitations and use
- This focused summary does not reproduce the full numerical HRT risk discussion aids or a complete dosing and monitoring protocol for individual products. Fezolinetant, testosterone and other treatment choices need their product-specific contraindications, monitoring and local approval status checked.
- The routine recommendations primarily concern women, trans men and non-binary people registered female at birth who have not used gender-affirming hormones. Past gender-affirming hormone treatment requires the separate specialist recommendations; current gender-affirming treatment is not addressed here.
- UK technology-appraisal access and prescribing labels need local adaptation in India. Menopause symptoms do not eliminate the need to investigate atypical bleeding or to assess depression, cancer risk and other alternative explanations.
This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.
Summary sources
- Menopause: identification and management
Selected recommendation material consulted
Publication details
- Issuing organisation
- NICE
- First published
- 12 November 2015
- Publisher’s latest update
- 15 April 2026
- Resource type
- Clinical guideline · House clinical summary
The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.